AUS
NZ
UK
CA
USA
IND
Highlights
- FDA clearance sets stage for U.S. entry into $1.6B nerve repair market
- Manufacturing scaled to meet growing global demand
- Strong cash reserves support expansion without extra funding
Orthocell (ASX:OCC) is entering a pivotal phase of growth following the recent U.S. Food and Drug Administration (FDA) clearance of its flagship Remplir™ nerve repair device. Granted under the FDA’s 510(k) pathway on April 3, 2025, the approval allows Orthocell to begin commercial distribution of Remplir™ in the lucrative US$1.6 billion American nerve repair market.
This milestone comes on the heels of a strong March 2025 quarter, positioning the regenerative medicine specialist to generate its first U.S. revenue from Remplir™ within the current financial year. The company has prepared extensively for this moment, with a U.S.-based commercial team in place since late 2024 and logistics already operational.
To meet anticipated demand, Orthocell has scaled up its manufacturing capability to produce up to 100,000 Remplir™ units annually, while maintaining the flexibility for further expansion. Significant inventory was also built up during the quarter in anticipation of the FDA clearance, ensuring swift market entry.
Orthocell showcased Remplir™ at a high-profile pre-launch event at the 2025 IFSSH and IFSHT Triennial Congress, drawing strong interest from the clinical community. Feedback from surgeons in Australia, where Remplir™ is already in use, has remained positive and consistent, reinforcing expectations for uptake in the U.S. market.
Financially, the company reported A$2.22 million in revenue for the quarter—marking its fourth consecutive quarter of strong performance and a 38% increase from the same period last year. This growth has been driven by increasing adoption of both Remplir™ and the Striate+™ dental membrane, particularly in the domestic market.
Net operating cash inflow totaled A$605,000, supported by Australia’s R&D Tax Incentive program. Orthocell concluded the quarter with a healthy A$31.7 million in cash and no debt, providing a solid financial foundation for global expansion without the need for additional capital raising.
Expansion efforts are also underway in other key markets, with regulatory submissions lodged for Remplir™ in Canada and Thailand—targeting market entries by the end of 2025. Meanwhile, Striate+™ continues its global rollout through international distribution channels, with recent regulatory approvals in Singapore and first sales in Germany, Austria, and Switzerland.
Capping off a strong quarter, Orthocell was added to the S&P/ASX All Ordinaries Index in March 2025—further cementing its status as a rising force in the biotech sector.
